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Background: Pancreatic cancer is characterized by constitutive activation of mitogen-activated protein kinase
(MAPK). Activation of MAPK is associated with the upregulation of genes implicated in the proliferation and survival
of pancreatic cancer cells. We hypothesized that knockdown of these MAPK-associated molecules could produce
notable anticancer phenotypes.
Methods: A RNA interference-mediated knockdown screening of 78 MAPK-associated molecules previously
identified was performed to find molecules specifically associated with proliferation of pancreatic cancer cells
in vitro. Expression of an identified molecule in pancreatic cancer tissues was examined by immunohistochemistry.
In vivo tumorigenicity of cancer cells with stable knockdown of the molecule was assayed by using xenograft
models. Flow cytometry and live cell imaging were employed to assess an association of the molecule with cell
cycle.
Results: The knockdown screening revealed that knockdown of SON, the gene encoding SON, which is a large
serine/arginine-rich protein involved in RNA processing, substantially suppressed pancreatic cancer cell proliferation
and survival in vitro and tumorigenicity in vivo. SON expression was higher in ductal adenocarcinomas than in cells
of normal ducts and precursor lesions in pancreatic cancer tissues. Knockdown of SON induced G2/M arrest and
apoptosis in cultured cancer cells. The suppressive effect of SON knockdown on proliferation was less pronounced
in cultured normal duct epithelial cells. SON formed nuclear speckles in the interphase of the cell cycle and
dispersed in the cytoplasm during mitosis. Live cell imaging showed that SON diffusely dispersed in the early
mitotic phase, accumulated in some foci in the cytoplasm in the late mitotic phase, and gradually reassembled into
speckles after mitosis.
Conclusion: These results indicate that SON plays a critical role in the proliferation, survival, and tumorigenicity of
pancreatic cancer cells, suggesting that SON is a novel therapeutic molecular target for pancreatic cancer.
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Pancreatic cancer is a leading cause of cancer-related
deaths [1,2]. Despite advancements in diagnostic and
therapeutic modalities, the 5-year survival rate of
patients with pancreatic cancer is less than 10% [3]. This
poor prognosis elicits an urgent need for the develop-
ment of effective diagnostic and therapeutic measures to
improve patient survival. Molecular medicine may be
able to fulfill this need, as exemplified by imatinib in the
treatment of chronic myeloid leukemia [4]. Pancreatic
cancer is characterized by constitutive activation of
mitogen-activated protein kinase (MAPK), due to gain-
of-function mutations in KRAS or BRAF and loss-of-
function of dual specificity phosphatase 6 (DUSP6) [5-7].
Active MAPK translocates to the nucleus, activates tran-
scription factors, and induces the expression of a variety
of genes [8]. In a previous study, we screened the gen-
ome for downstream targets of MAPK and identified 78
molecules specifically associated with MAPK activity in
pancreatic cancer cells [9]. These MAPK-associated
molecules include molecules implicated in DNA replica-
tion, RNA editing, spindle formation, mitosis, signal
transduction, and membrane trafficking. These bio-
logical processes play critical roles in the survival, main-
tenance, and proliferation of pancreatic cancer cells. We
hypothesized that molecular targeting of these MAPK-
associated molecules could result in notable anticancer
phenotypes, as we previously observed by targeting
AURKA [9,10]. In this study, we performed a systematic
knockdown screening of MAPK-associated molecules in
pancreatic cancer cells.
Results
Knockdown screening of MAPK-modulated genes in
pancreatic cancer cells
We performed knockdown screening using a pancreatic
cancer cell line, MIA PaCa-2, and custom-designed shortFigure 1 Knockdown screening of MAPK-associated genes in pancrea
line, transfected with siRNA targeting various genes associated with MAPK
day 5 post-transfection. Plotted values are expressed relative to cells infecte
represent an average of 2 independent experiments; each experiment inclu
(closed column) showed the most remarkable anti-proliferative phenotype.interfering RNAs (siRNAs) targeting all the 78 MAPK-
modulated genes that were previously identified and iso-
lated in the cell line (Additional file 1: Table S1) [9]. The
cells were transiently transfected with each of the 78
siRNAs, and in vitro proliferation was subsequently
examined for 5 consecutive days. This screening showed
that proliferation of cancer cells was suppressed to vari-
able degrees depending on the individual gene targeted
(Figure 1). Knockdown of AURKB, CENPA, EBNA1BP2,
GOLT1A, KIF11, NEDD4L, SON, TPX2, or WDR5 sup-
pressed proliferation by more than 50% compared with
control. Among these targets, we focused on SON for
further study because it showed the most substantial
suppressive effect. This gene encodes a nuclear speckle
protein, SON, which is involved in RNA processing.
Knockdown of SON attenuates proliferation in vitro,
considerably in pancreatic cancer cells but less
remarkably in normal phenotype cells
The in vitro suppressive effect of siRNA targeting SON
on proliferation was reanalyzed in detail by using MIA
PaCa2; PCI-35, a pancreatic cancer cell line with an ag-
gressive phenotype; and HPDE, an immortalized normal
human pancreatic duct epithelial cell line [7,11-13]. The
suppressive effects of SON knockdown on cell prolifera-
tion appeared to be fatal in MIA PaCa-2, static in PCI-
35, and insignificant in HPDE (Figure 2A). The effects of
siRNA on SON expression were assayed by an immuno-
blotting method, which showed 77%, 10%, and 48% re-
duction of SON expression in MIA PaCa-2, PCI-35, and
HPDE, respectively (Figure 2B). These results indicated
that SON knockdown attenuated the in vitro prolifera-
tion of pancreatic cancer cells. The attenuation of prolif-
eration depended on the efficiency of SON knockdown
in pancreatic cancer cells, but was less remarkably
affected in normal phenotype cells.tic cancer cells. Proliferation of MIA PaCa-2, a pancreatic cancer cell
(indicated on the horizontal axis), was determined by MTT assay on
d with control siRNA to a nonspecific sequence (Nonsp). Plots
des data from 8 independent transfection wells. Knockdown of SON
Figure 2 A. Proliferation of pancreatic cancer cells (MIA PaCa-2 and PCI-35) and normally phenotypic duct epithelial cells (HPDE)
transfected with siRNA against SON (siSON) or a nonspecific sequence (siNons) and measured by MTT assay. The plots represent an
average of 2 independent experiments; experiment includes data from 8 independent transfection wells. B. Expression of SON in cells transfected
with siSON or siNons is shown in immunoblots probed with anti-SON antibody (SON) or anti-beta actin antibody (ACTB). C. Colony formation
assay of pancreatic cancer cells transfected with vectors expressing shRNA targeting SON (shSON) or a non-specific sequence (shNons).
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pancreatic cancer cells in vitro
We next constructed a vector expressing short hairpin
RNA (shRNA) identical to the SON siRNA when pro-
cessed. We examined the effect of stable knockdown of
SON on the survival of pancreatic cancer cells in vitro
using a colony formation assay. We found that stable
knockdown of SON strongly attenuated the survival of
cancer cells, even in PCI-35 cells, in which transient
transfection of siRNA targeting SON modestly sup-
pressed proliferation (Figure 2C).
SON is overexpressed in pancreatic ductal
adenocarcinomas
To establish the native expression of SON in pancreatic
cancer, we examined 34 tissues with pancreatic ductal
adenocarcinoma that were surgically resected. Immuno-
histochemistry showed that SON was strongly expressed
in the nuclei of cancer cells in most ductal adenocarcin-
omas significantly more obviously than in the nuclei of
non-neoplastic ducts or pancreatic intraepithelial neopla-
sia (PanIN), a precursor lesion of ductal adenocarcinoma(p < 0.001 by ANOVA) (Figure 3 and Table 1). This result
indicates that SON is specifically overexpressed in pancre-
atic cancer.
Knockdown of SON retards the tumorigenicity of
pancreatic cancer cells in vivo
We then performed a tumorigenicity assay using stably
transfected pancreatic cancer cell clones carrying the
shRNA vector targeting SON. Several stably transfected
clones of MIA PaCa-2 and PCI-35 cells were obtained,
and expression of SON was determined by real-time
quantitative PCR. SON expression was lowest, reduced
by 50%, in an MIA PaCa-2 clone (Figure 2D). We could
not obtain any stably transfected PCI-35 clones in which
SON expression was obviously reduced. This was prob-
ably because PCI-35, unlike MIA PaCa-2, could not sur-
vive modest knockdown of SON, which strongly
suppresses the survival of cancer cells in vitro. The sta-
bly transfected clone of MIA PaCa-2 was inoculated into
the subcutis of nude mice, and tumorigenicity was moni-
tored. After 4 weeks, tumorigenicity was significantly
retarded (Figure 4A).
Figure 3 Immunohistochemical examination of SON expression in pancreatic cancer tissues. Diaminobenzidine and hematoxylin was used
as a chromogen and a counter stain, respectively. A and B. Ductal adenocarcinomas (ducts labeled in C) strongly express SON in nuclei, more
obviously than normal ductal cells (ducts labeled in N). The normal duct in panel B was partially (lower half) involved with carcinoma cells
(original magnification, 100×). C. A high-powered view of ductal adenocarcinoma shows strong expression of SON in nuclei (original
magnification, 200×). D. Pancreatic intraepithelial neoplasia, a precursor lesion of ductal adenocarcinoma, shows less obvious expression of SON
(original magnification, 100×).
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and apoptosis
To determine the mechanism by which SON knockdown
suppresses the proliferation and survival of pancreatic
cancer cells, the DNA content of siRNA-transfected
MIA PaCa-2 and PCI-35 cells was measured by flow
cytometry, and the cell cycle was assessed. Knockdown
of SON increased the fraction of cells in G2/M and sub-
G1, indicating that the cells were in G2/M arrest and
apoptosis (Figure 4B).
SON shuttles between the nucleus and cytoplasm
depending on the cell cycle
To investigate the dynamics of intracellular SON expres-
sion and its role in mitosis, a vector expressing SON,
tagged with enhanced green fluorescence protein (EGFP)
at the amino terminus (EGFP-SON), was constructed
and transfected into 293 cells. The dynamics ofTable 1 Expression of SON in ductal lesions evaluated by
immunohistochemistry
Ductal lesion Total
number
of lesions
Intensity score P
(ANOVA)1,
weak
2,
moderate
3,
strong
Ductal
adenocarcinoma
34 0 3 31 < 0.001
PanIN 23 15 8 0
Normal 29 24 5 0intracellular SON expression were then analyzed. Ex-
pression of EGFP-SON was confirmed by immunoblot-
ting by using specific antibodies against SON or EGFP
(Figure 5A). Confocal laser scanning images showed that
EGFP-SON was expressed as speckles in the nuclei of
cells in the interphase and was dispersed in the cyto-
plasm of cells in the mitotic phase (Figure 5B). Time-
lapse live imaging of cells expressing EGFP-SON showed
that SON dispersed diffusely in the cytoplasm in meta-
phase and anaphase, accumulated in some foci in the
cytoplasm during telophase and cytokinesis, and grad-
ually reassembled in nuclear speckles after cytokinesis as
foci in the cytoplasm faded (Figure 5C). From meta-
phase, the reassembly into nuclear speckles took ap-
proximately 2 hours. These results indicate that SON
shuttles between the nucleus and the cytoplasm depend-
ing on the phase of the cell cycle, transitioning from nu-
clear speckles and through diffuse dispersion and
subsequent temporal accumulation in the cytoplasm, to
slow reassembly into nuclear speckles during mitosis
and the early G1 phase.
Discussion
In this study, among many genes associated with MAPK,
we found that knockdown of SON remarkably suppressed
the proliferation, survival, and tumor formation of pancre-
atic cancer cells. The suppressive effect was less pro-
nounced in normally phenotypic ductal cells. In primary
pancreatic cancer tissues, SON was overexpressed in
Figure 4 A. Left panel: Expression of SON in cloned cells (MIA PaCa-2) stably transfected with shSON or shNons. Middle panel: An
example image of a nude mouse with a xenograft of MIA PaCa-2 clones stably transfected with shSON or shNons at 4 weeks after inoculation in
the subcutis. Right panel: Average growth of tumors from xenografts of MIA PaCa-2 cells stably transfected with shSON or shNons in the subcutis
of 4 nude mice. One (*) and 2 (**) asterisks indicate p < 0.05 and p < 0.01, respectively. Error bars denote 1 value of standard error. B. Cell cycle
fractions of pancreatic cancer MIA PaCa-2 and PCI-35 cells transfected with short interfering RNA (siRNA) against SON (siSON) or a nonspecific
sequence (siNons) as determined by flow cytometry.
Figure 5 A. Immunoblot of total cell lysate from 293 cells transfected with pEGFP vector or pEGFP-SON probed with antibodies
against EGFP or SON. B. Fluorescence images of 293 cells transfected with pEGFP-SON or pEGFP-vector. Note that EGFP-SON was speckled in
the nuclei of interphase cells and diffusely dispersed in mitotic cells. Original magnification, 600×. C. Time-lapse images of 293 cells transfected
with EGFP-SON. Sequential images taken at 10-minute intervals are shown (the number on each image indicates minutes from starting).
EGFP-labeled SON dispersed in the cytoplasm during metaphase and anaphase (panels at 0 and 10 minutes), accumulated in small foci in the
cytoplasm during telophase and cytokinesis (panels between 20 and 50 minutes), and then gradually reassembled in nuclear speckles (panels at
60 minutes and later). Original magnification, 400×.
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and PanINs. Knockdown of SON induced G2/M arrest
and apoptosis. SON shuttled between the nucleus and
cytoplasm depending on the phase of cell cycle. These
results indicate that SON plays a crucial role in the
proliferation, survival, and tumorigenicity of pancreatic
cancer cells, thus suggesting that this molecule could
be a prime therapeutic molecular target for pancreatic
cancer.
Our investigation showed that knockdown of MAPK-
associated molecules suppressed the proliferation of
pancreatic cancer cells in vitro to variable degrees. We
found that knockdown of AURKB, CENPA, EBNA1BP2,
GOLT1A, KIF11, NEDD4L, SON, TPX2, or WDR5
strongly suppressed the proliferation. AURKB encodes
aurora kinase B (AURKB), which is involved in chromo-
some segregation and cytokinesis during mitosis [14].
CENPA encodes centromere protein A (CENPA), which,
by functioning as a replacement for histone H3 in
centromeric nucleosomes, plays an essential role in kin-
etochore formation and functions in cellular mitosis
[15]. EBNA1BP2 encodes a ribonucleoprotein, Epstein-Barr
virus nuclear antigen 1-binding protein 2 (EBNA1BP2),
which serves as a scaffold for ribosome biogenesis [16].
GOLT1A encodes Golgi transport 1A (GOLT1A), which
functions as a transporter on the Golgi membrane [17].
KIF11 encodes a microtubule-dependent motor protein,
kinesin family member 11 (KIF11), which plays a critical
role in chromosome positioning during mitosis [18].
NEDD4L encodes neural precursor cell expressed, develop-
mentally down-regulated 4-like, an E3 ubiquitin protein lig-
ase (NEDD4L) that plays a role in polyubiquitination and
proteasomal destruction of SMAD2/3 [19]. TPX2
encodes a homologue of Tpx2 of Xenopus (TPX2), a
binding partner of aurora kinase A (AURKA) that
plays a role in microtubule spindle formation [20].
WDR5 encodes WD repeat domain 5 (WDR5), which
binds methylated histone H3 lysine 4 (H3K4) and is
required for recruiting H3K4 methyltransferase [21].
Among these, AURKB, CENPA, KIF11, and TPX2
are involved in functions of the microtubule spindles
and kinetochores, which are considered essential for
cell mitosis. Because we screened by assaying the
effects of knockdown of the MAPK-associated genes
on in vitro proliferation of pancreatic cancer cells,
molecules associated with the microtubules and
kinetochores might be selectively represented in our
screening. Interestingly, these microtubule kinetochore-
associated molecules have already been studied as molecu-
lar targets in various cancers [22-25]. Nevertheless, of these
MAPK-associated molecules, we found that knockdown of
SON most remarkably suppressed proliferation, which led
us to investigate SON in detail as a candidate molecular
target.SON encodes SON, a large protein harboring a serine
or arginine-rich domain. It was first cloned as a gene en-
coding a protein with DNA-binding activity. However,
subsequently, it turned out to be a nuclear speckle pro-
tein involved in RNA processing and required for proper
and efficient splicing of pre-mRNAs [26-30]. In our
study, knockdown of SON attenuated the proliferation,
survival, and tumorigenicity of pancreatic cancer cells.
These suppressive effects were attributable to cell cycle
arrest at the G2/M phase and apoptosis induced by de-
pletion of SON. The association between the depletion
of SON and G2/M arrest has been reported to be asso-
ciated with impairment of spindle pole separation,
microtubule dynamics, and genome integrity due to
inadequate RNA splicing of a specific set of cell cycle-
related genes with weak splice sites, i.e., splice sites with-
out the conserved sequence [30].
Pancreatic cancer cells were more susceptible to deple-
tion of SON than normally phenotypic cells. This may
be due to rapid progression through the cell cycle in
cancer cells, which results in exaggerated dependence on
SON to maintain efficient RNA processing of the cell
cycle-related genes. This interpretation could be
endorsed by the overexpression of SON we found in
most ductal adenocarcinomas, compared with normal
ductal cells or precursor lesions, which suggests that
adenocarcinoma cells depend on SON more strongly
than normal ductal cells and precursor lesions to main-
tain their phenotypes. These results suggest that deple-
tion of SON may specifically lead to an anticancer
phenotype. SON overexpression is purportedly due to
the constitutive activation of MAPK in ductal adenocar-
cinoma; however, other possible causes, such as gene
amplification or aberrations in protein turnover, cannot
be ruled out and will be a subject of further study.
The dynamics of SON distribution during the cell
cycle is not well known. We performed live-cell imaging
of cells expressing EGFP-SON and observed that SON
dispersed in the cytoplasm during early mitotic phase
formed small foci in the cytoplasm in the late mitotic
phase, and gradually redistributed as speckles in the nu-
cleus as foci in the cytoplasm faded. The cytoplasmic
small foci are supposed to be mitotic interchromatin
granules that correspond to accumulations of nuclear
speckle proteins in the cytoplasm in the late mitotic
phase [31,32]. These dynamics seem similar to the dy-
namics of another speckle protein, SF2, and are consist-
ent with the idea that SON plays a role in the
appropriate organization of RNA splicing factors
[29,33,34].
The knockdown of SON by RNA interference showed
sufficient anti-cancer phenotypes experimentally. For the
RNA interference, vector-mediated stable transduction
appeared to be more effective than oligonucleotide-based
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stable knockdown of SON by RNA interference could be
an efficient molecular therapy for pancreatic cancer, the
lack of a conventional method for tissue-specific, stable de-
livery of short, double-stranded RNA could limit the use of
this approach in clinical therapeutics. Indeed, the use of
RNA interference in clinical practice is generally not war-
ranted. Recently, however, systemic delivery of siRNA com-
bined with a special nanoparticle successfully knocked
down a target gene in melanoma in a clinical trial [35].
The use of such a technique to attempt specific knock-
down of SON in pancreatic cancer cells in a clinical model
is worth trying and is an issue to be resolved in a future
study. The results of this study also suggest that develop-
ment of a molecule-oriented chemical substance against
SON as therapy for pancreatic cancer is warranted.
Conclusion
This study indicates that SON is overexpressed and
plays a critical role in the proliferation, survival, and
tumorigenicity of pancreatic cancer cells, suggesting that
SON is a novel therapeutic molecular target for pancre-
atic cancer.
Methods
Cell culture
Human pancreatic cancer cell lines, MIA PaCa-2 and
PCI-35, and the human embryonic kidney cell line 293
were obtained and cultured as previously described [7,9].
The immortalized human pancreatic duct-epithelial cell
line, HPDE, was kindly provided by Dr. MS Tsao (Princess
Margaret Hospital and Ontario Cancer Institute, Toronto,
ON) and cultured as previously described [12].
Transfection of siRNA and cell proliferation assay
siRNAs targeting each downstream MAPK-associated
molecule were custom designed and manufactured
(RNAi Co. Ltd., Tokyo, Japan) (Additional file 1: Table S1).
Cells were seeded at 5 × 103 cells/well in 96-well plates
with 100 μL of appropriate culture medium and incubated
at 37°C with 5% CO2 for 24 hours. Then, the medium was
replaced with OPTI-MEM (Life Technologies, Carlsbad,
CA), and the cells were transfected with siRNA at 10 nM
with Oligofectamine (Life Technologies) according to the
manufacturer’s recommendations. After 4 hours of incu-
bation, the transfection reagent was replaced with the ap-
propriate culture medium. A colorimetric cell proliferation
assay—3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay—was performed daily for 5 days as
previously described [7].
Colony formation assay with shRNA vectors
pSUPER vector (Oligoengine, Seattle, WA) was used for
the construction of vectors expressing shRNAs bycloning the oligonucleotides 50-GATCCCCGCATCTA
GACGTTCTATGATTCAAGAGATCATAGAACGTCT
AGATGCTTTTTA-30 and 50-AGCTTAAAAAGCATC
TAGACGTTCTATGATCTCTTGAATCATAGAACGTC
TAGATGCGGG-30 to target SON (shRNA-SON), and
50-GATCCCCGTACCGCACGTCATTCGTATTCAAG
AGATACGAATGACGTGCGGTACTTTTTA-30 and
50-AGCTTAAAAAGTACCGCACGTCATTCGTATCTCT
TGAATACGAATGACGTGCGGTACGGG-30 to serve as
a control harboring a nonspecific sequence against the
human genome (shRNA-Nons) according to the manufac-
turer’s instructions. MIA PaCa-2 and PCI-35 cells were
seeded at 1 × 105 cells/well in 6-well plates and incubated
for 24 hours at 37°C with 5% CO2. The shRNA-SON vec-
tor or shRNA-Nons vector were transfected into the cells
with LipofectamineTM reagent (Life Technologies) accord-
ing to the manufacturer’s recommendations. The cells
were dissociated with trypsin 48 hours after transfection
and reseeded in three 10-cm tissue-culture dishes, con-
taining the appropriate culture medium supplemented
with 10% FBS and G418 (Life Technologies) at 400 μg/mL
for PCI-35 and 500 μg/mL for MIA PaCa-2. After 3 weeks,
the cells were fixed with 10% formalin solution and
stained with hematoxylin. The number of colonies was
assessed with the COLONY program (Fujifilm Co. Ltd.,
Tokyo, Japan).
Immunohistochemistry
Thirty-four formalin-fixed, paraffin-embedded tissues of
pancreatic ductal adenocarcinoma that were surgically
resected during 2006 and 2007 at Tokyo Women’s Med-
ical University Hospital were studied. Indirect immuno-
histochemical staining was performed as previously
described [36] by using a polyclonal anti-SON antibody
(1:1200 dilution, Sigma, St. Louis, MO), a secondary
antibody against rabbit immunoglobulin (Nichirei,
Tokyo, Japan), and streptavidin solution (Nichirei). Use
of the archival pathological tissues was approved by the
ethics committee of Tokyo Women’s Medical University.
Immunohistochemical results were evaluated among
ductal lesions classified into adenocarcinoma, PanIN, or
normal duct by scoring intensities of staining into 1,
weak; 2, moderate; and 3, strong by comparing with nor-
mal ductal cells that showed weak staining or acinar
cells that showed moderate staining. The scores were
statistically analyzed by ANOVA by using PASW Statis-
tics software (IBM Japan, Tokyo, Japan).
Quantitative real-time polymerase chain reaction assay
The TaqMan Gene Expression Assay and a 7500 Real-
time PCR system (Life Technologies) were used to
analyze the transcriptional expression of SON by using
the absolute quantitative assay according to the manu-
facturer’s instructions. The expression of SON was
Furukawa et al. Molecular Cancer 2012, 11:88 Page 8 of 10
http://www.molecular-cancer.com/content/11/1/88assessed relative to the endogenous expression of
GAPDH.
In vivo tumorigenicity assay
Pancreatic cancer cells stably transfected with shRNA
vectors were isolated by cloning the surviving cells from
the colony formation assay. These clones, in 50% matri-
gel/culture medium without FBS, were inoculated into
the subcutis of BALB/c nude mice (Clea Japan Inc.,
Tokyo, Japan). Tumorigenicity was monitored weekly,
and the tumor volume was calculated using the follow-
ing formula: V = D × d2 × 0.4 (V, tumor volume; D, lar-
gest dimension; d, smallest dimension).
Flow cytometry
Flow cytometric analyses for cell cycle and apoptosis
were performed as previously described [7].
Construction of the EGFP-SON vector
An expression vector containing the full coding sequence
of SON cDNA (NM_138927) was constructed by assem-
bling amplified products using KOD Plus DNA Polymer-
ase and its specific buffer (TOYOBO, Osaka, Japan),
appropriate paired primers, and pooled cDNA obtained
from a fetal brain cDNA library (Stratagene/Agilent
Technologies Inc., Santa Clara, CA) as follows. Paired
primers used for amplification of cDNA fragments were
C51, 50-TTTAAGCTTATGGCGACCAACATCGAGCAG-
30 (melting temperature [Tm], 58°C) and C12, 50-
TAAGGGTGTTCTTGATCGCC-30 (Tm, 52°C); C7, 50-
AGCCGCCGGAGAAGATCAAGG-30 (Tm, 59°C) and
C10, 50-CAGGCTCTGAGGGCAAATTG-30 (Tm, 53°C);
and C5, 50-TAAACTCAGTGAACCCAAACC-30 (Tm, 50°
C) and C52, 50-TTTGGTACCTCAATACCTATTCAA
GAAAAACATAC-30 (Tm 48°C). Products amplified by
PCR were sequentially cloned into the pFLAG-CMV-4
vector (Sigma, St. Louis, MO) at HindIII-EcoRI-KpnI sites
to obtain pFLAG-SON. The pEGFP-C2 vector (Clontech,
Mountain View, CA) was modified by fill-in of its XhoI
site to adjust the reading frame. The coding region of
SON cDNA was prepared from pFLAG-SON by digestion
with HindIII and KpnI for the 30 fragment and HindIII for
the 50 fragment. These fragments were sequentially cloned
into the modified pEGFP-C2 vector at HindIII and KpnI
sites to obtain the pEGFP-SON vector. DNA sequences
were confirmed by using BigDyeW Terminator and a
3130x Genetic analyzer (Life Technologies).
Immunoblot
Denatured total cell lysate was separated in a 5–15%
polyacrylamide gel and blotted onto a polyvinylidene
fluoride membrane by using an XV Pantera MP System
(DRC Co., Ltd. Tokyo, Japan) according to the manufac-
turer’s recommendations. The blotted membrane wasprobed with anti-SON antibody (Sigma), anti-beta actin
antibody (Sigma), or anti-EGFP antibody (Clontech).
Horseradish peroxidase-conjugated anti-rabbit or anti-
mouse immunoglobulin antibodies (GE Healthcare UK
Ltd., Buckinghamshire, UK) were used for the secondary
antibody reaction. Blocking conditions and concentra-
tions of antibodies were determined according to the
manufacturers’ recommendations. Signals were visua-
lized by reaction with ECL Detection Reagent (GE
Healthcare UK Ltd.) and captured digitally by using an
LAS 4000 Mini (Fujifilm Co. Ltd.) or by autoradiog-
raphy. Intensities of bands were measured digitally using
Image Gauge software (Fujifilm Co. Ltd.).Laser scanning fluorescence imaging
The pEGFP-SON vector was transfected into 293 cells
using Lipofectamine Plus (Life Technologies) according
to the manufacturer’s recommendations. The transfected
cells were incubated with Eagle’s Minimum Essential
Medium (Sigma) supplemented with 10% FBS and
400 μg/mL G418. Stably transfected clones were
obtained by cloning surviving cells using a cylinder cup.
The isolated clones were seeded in a glass-bottom dish
and incubated for 24 hours. The cells were incubated
with a medium supplemented with 0.1 μg/mL Hoechst
33342 (Life Technologies) for 30 minutes. The medium
was then replaced with fresh growth medium and exam-
ined under a confocal laser scanning microscope (LSM5,
Carl-Zeiss Microimaging GmbH, Goettingen, Germany).
Time-lapse images were obtained for 2 layers at 0- and
5-μm depth with 10-minute intervals over a total of
230 minutes.Statistics
Student’s t-test was applied to analyze statistical differ-
ences using Statview 5.0 software (SAS Institute Inc.,
Cary, NC, USA). P values of <0.05 were considered sta-
tistically significant.Additional file
Additional file 1: Table S1. Short interfering RNAs used in a systematic
knockdown screening of MAPK-assoicated genes in pancreatic cancer.Abbreviations
AURKA: Aurora kinase A; AURKB: Aurora kinase B; CENPA: Centromere protein
A; DUSP6: Dual specificity phosphatase 6; EBNA1BP2: Epstein-Barr virus
nuclear antigen 1-binding protein 2; EGFP: Enhanced green fluorescence
protein; GOLT1A: Golgi transport 1A; H3K4: Histone H3 lysine 4; KIF11:
Kinesin family member 11; MAPK: Mitogen-activated protein kinase; MTT:
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; NEDD4L: Neural
precursor cell expressed, developmentally down-regulated 4-like, an E3
ubiquitin protein ligase; Nons: Non-specific sequence; PanIN: Pancreatic
intraepithelial neoplasia; shRNA: Short hairpin RNA; siRNA: Short interfering
RNA; TPX2: A homologue of Tpx2 of Xenopus; WDR5: WD repeat domain 5.
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